Source comparison
CJC-1295 vs Ipamorelin — Which Research Peptide Fits Your Lab?
Research published in the Journal of Clinical Endocrinology & Metabolism found that modified growth hormone-releasing hormone (GHRH) analogs like CJC-1295 extended growth hormone secretion for up to eight days after a single injection. A half-life profile that
This comparison does not assign a generated winner or score.
- Research published in the Journal of Clinical Endocrinology & Metabolism found that modified growth hormone-releasing hormone (GHRH) analogs like CJC-1295 extended growth hormone secretion for up to eight days after a single injection. A half-life profile that fundamentally changes how researchers structure dosing protocols compared to traditional growth hormone secretagogues. That duration isn't a minor technical detail: it's the central consideration when choosing between CJC-1295 and Ipamorelin for studies examining sustained versus pulsatile GH dynamics.
- We've worked with hundreds of research teams sourcing peptides for GH-related studies. The confusion between CJC-1295 and Ipamorelin stems from their shared classification as growth hormone secretagogues. But their mechanisms, kinetics, and appropriate applications differ substantially.
- What's the difference between CJC-1295 and Ipamorelin?
- CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog that binds to serum albumin, extending its half-life to five to eight days and producing sustained elevation of GH levels. Ipamorelin is a growth hormone secretagogue receptor (GHSR) agonist. Commonly called a ghrelin mimetic. That triggers acute, pulsatile GH release lasting 90–120 minutes per dose. CJC-1295 mimics the body's baseline GHRH signaling and maintains elevated GH over days, while Ipamorelin replicates the body's natural GH pulses without affecting cortisol or prolactin.
- The direct answer: if your study requires steady-state GH elevation with minimal dosing frequency, CJC-1295 is the standard choice. If you're modeling physiological GH pulse dynamics or need to isolate acute anabolic signaling windows, Ipamorelin provides that specificity without the extended systemic exposure.
- Most peptide comparison guides stop at 'both boost GH'. But that oversimplifies the pharmacokinetic and receptor-level differences that determine whether your study protocol will produce replicable, interpretable data. This article covers the molecular mechanisms that differentiate these compounds, the dosing schedules that match each peptide's kinetic profile, and the storage and reconstitution protocols that preserve stability across multi-week studies.